Skip to content
Bored Studies
RecruitingPhase 1/Phase 2

Pegtibatinase as a Treatment for Patients With Classical Homocystinuria (HCU) (Also Known as the COMPOSE Study)

Travere Therapeutics, Inc. · NCT03406611

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 5–65 · All sexes
Healthy volunteers
Not accepted (a condition is required)
Study type
Interventional · Phase 1, Phase 2
Target enrollment
39
US sites recruiting
1
Study start
January 22, 2019
Record last updated
August 10, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

Researchers are looking for a better way to treat people who have classical homocystinuria (HCU), a rare condition that is passed down by parents (or "genetic condition"). It is caused by changes in the cystathionine beta-synthase (or "CBS") gene and prevents an enzyme from working correctly in the body. This enzyme breaks down a substance called homocysteine (from dietary methionine found in protein) and keeps both homocysteine and methionine at normal levels. When this enzyme is not working, homocysteine and methionine build up in the blood, which spreads into different tissues of the body and stops these body tissues from working normally.

People with HCU can experience problems with vision, bones, blood vessels, and cognitive function (the ability to think, learn, and remember). Treatments available for HCU, such as a low protein diet and betaine (Cystadane®), help reduce homocysteine levels. The diet is a low methionine diet and a methionine-free protein supplement (a product that provides extra protein to help meet daily protein needs). These treatments are either not sufficient or are hard to take for many patients.

Pegtibatinase was developed by scientists to be a version of the CBS enzyme that can be given to people with HCU. Researchers believe that giving pegtibatinase to people with HCU already getting medical treatment (or "standard of care") may reduce their homocysteine levels.

This study is split into 7 different groups getting different amounts of drug. The first 6 groups have already finished the study.

Group 7 plans to enroll participants from the US (virtual and in-person), France, and Qatar.

Being studied: Pegtibatinase; Placebo

Conditions: Homocystinuria

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria

  • Age
  • Cohort 7 (currently enrolling): ≥5 to \<12 years of age.
  • Completed Cohorts 1-6: ≥12 to 65 years of age.
  • Diagnosis of classical homocystinuria (HCU)
  • Cohort 7 (currently enrolling): Diagnosis based on clinical, biochemical, and/or molecular genetic testing.
  • Completed Cohorts 1-6: Genetically confirmed cystathionine beta-synthase (CBS)-deficient HCU.
  • Plasma total homocysteine (tHcy)
  • Cohort 7 (currently enrolling): Plasma tHcy ≥50 μM at Screening.
  • Completed Cohorts 1-6: Plasma tHcy ≥50 μM at Screening and documented historical plasma tHcy ≥80 μM.
  • Willing and able (or parent/legal guardian willing and able) to provide informed consent/assent and comply with study procedures.
  • Willing to maintain a generally stable standard-of-care treatment regimen, including dietary management and HCU-related therapies, unless changes are medically necessary.
  • Participants of childbearing potential must have a negative pregnancy test before study treatment and agree to use protocol-specified contraception, if applicable.

Exclusion Criteria

Cohort 7 only:

  • Diagnosis of Marfan syndrome, methylenetetrahydrofolate reductase (MTHFR) deficiency, or a disorder of cobalamin metabolism.
  • History of a major thrombotic event within the previous 6 months.
  • Body weight \<15 kg.

All Cohorts

  • Previous treatment with pegtibatinase or pegtarviliase)
  • Participation in a pegtibatinase clinical study.
  • Receipt of another investigational drug or investigational medical device within 30 days before Screening or planned use during study participation.
  • Use of injectable polyethylene glycol (PEG)-containing medications (other than pegtibatinase or PEG-containing vaccines) within 3 months before Screening or during study participation.
  • Known hypersensitivity to pegtibatinase or a history of severe hypersensitivity to a PEG-containing product.
  • Active HIV, hepatitis B, or hepatitis C infection.
  • History of organ transplantation or immunosuppressive therapy.
  • Clinically significant medical conditions that could interfere with study participation or participant safety.
  • Pregnant or breastfeeding, or planning to become pregnant during study participation.
  • Major surgery planned during the study period.
  • Any condition that could prevent the participant from complying with study procedures or completing the study.

Recruiting US locations

Study contacts (from the official record)

  • Travere Call Center · 1-877-659-5518 · medinfo@travere.com
All phase 1 studies in North Carolina →
Pegtibatinase as a Treatment for Patients With Classical… (NCT03406611) | Bored Studies